1339947-25-9Relevant academic research and scientific papers
Dihydroxy dimethyl isochroman-3-formyl-Phe as well as preparation, anti-ischemic stroke effect and application thereof
-
Paragraph 0015-0016, (2021/01/29)
The invention discloses (R)-6,7-dihydroxy-1,1-dimethyl isochroman-3-formyl-Phe represented by the following formula, a preparation method of the (R)-6,7-dihydroxy-1,1-dimethyl isochroman-3-formyl-Pheand a treatment effect of the (R)-6,7-dihydroxy-1,1-dimethyl isochroman-3-formyl-Phe on rats suffering from ischemic stroke for 24 hours. Therefore, the invention discloses an application of the compound in preparation of drugs which are still effective for 24 hours after ischemic stroke attack.
Preparation, antithrombotic activity and application of dihydroxy dimethyl isochroman-3-formyl-Met
-
Paragraph 0014; 0016-00117, (2021/01/29)
The invention discloses (R)-6,7-dihydroxy-1,1-dimethyl isochroman-3-formyl-Met represented by the following formula, a preparation method of the (R)-6,7-dihydroxy-1,1-dimethyl isochroman-3-formyl-Met,an antithrombotic effect of the (R)-6,7-dihydroxy-1,1-dimethyl isochroman-3-formyl-Met, and an application of the (R)-6,7-dihydroxy-1,1-dimethyl isochroman-3-formyl-Met to preparation of antithrombotic drugs.
Dihydroxy dimethyl isochroman-3-formyl non-polar amino acid as well as preparation, antithrombotic activity and application thereof
-
Paragraph 0015; 0017-0018, (2021/01/29)
The invention discloses three (R)-6,7-dihydroxy-1,1-dimethyl isochroman-3-formyl-AA (AA is L-Ala, Gly and L-Ile residues) represented by the following formula, a preparation method of the (R)-6,7-dihydroxy-1,1-dimethyl isochroman-3-formyl-AA, an antithrombotic effect of the (three (R)-6,7-dihydroxy-1,1-dimethyl isochroman-3-formyl-AA, and an application of the three (R)-6,7-dihydroxy-1,1-dimethylisochroman-3-formyl-AA.
Dihydroxy dimethyl isochroman-3-formyl non-polar amino acid as well as preparation, thrombolytic activity and application thereof
-
Sheet 0015; 0017; 0018, (2021/01/29)
The invention discloses six (R)-6,7-dihydroxy-1,1-dimethyl isochroman-3-formyl-AA (L-Ala, L-Gly, L-Ile, L-Leu, L-Pro and L-Val residues) represented by the following formula, a preparation method of the (R)-6,7-dihydroxy-1,1-dimethyl isochroman-3-formyl-AA and a thrombolytic effect of the (R)-6,7-dihydroxy-1,1-dimethyl isochroman-3-formyl-AA. Therefore, the invention discloses an application of the (R)-6,7-dihydroxy-1,1-dimethyl isochroman-3-formyl-AA in preparation of thrombolytic drugs.
Dihydroxy dimethyl isochroman-3-formyl polar amino acid as well as preparation, antithrombotic activity and application thereof
-
Paragraph 0014; 0016; 0017, (2021/01/29)
The invention discloses five (R)-6,7-dihydroxy-1,1-dimethyl isochroman-3-formyl-AA (AA is L-Asp, L-Glu, L-Asn, L-Arg and L-Ser residues) represented by the following formula, a preparation method of the (R)-6,7-dihydroxy-1,1-dimethyl isochroman-3-formyl-AA and an antithrombotic effect of the (R)-6,7-dihydroxy-1,1-dimethyl isochroman-3-formyl-AA. Therefore, the invention discloses an application ofthe (R)-6,7-dihydroxy-1,1-dimethyl isochroman-3-formyl-AA in preparation of antithrombotic drugs.
Dihydroxy dimethyl isochroman-3-formyl-AA as well as preparation, ischemic stroke resisting effect and application thereof
-
Paragraph 0012; 0014-0015, (2021/01/29)
The invention discloses three (R)-6,7-dihydroxy-1,1-dimethyl isochroman-3-formyl-AA (AA in the formula is L-Asp, L-Asn and L-Ser residues) represented by the following formula, a preparation method ofthe (R)-6,7-dihydroxy-1,1-dimethyl isochroman-3-formyl-AA, and a treatment effect of the (R)-6,7-dihydroxy-1,1-dimethyl isochroman-3-formyl-AA on ischemic stroke attack for 24 hours. Therefore, the invention discloses an application of the compounds in preparation of medicines which are still effective for 24 hours after ischemic stroke attack.
Dihydroxy dimethyl isochroman-3-formyl aromatic amino acid as well as preparation, antithrombotic activity and application thereof
-
Paragraph 0014; 0016-0017, (2021/01/29)
The invention discloses four (R)-6,7-dihydroxy-1,1-dimethyl isochroman-3-formyl-AA (AA is L-Phe, L-His, L-Trp and L-Tyr residues) represented by the following formula, a preparation method of the (R)-6,7-dihydroxy-1,1-dimethyl isochroman-3-formyl-AA, and an antithrombotic effect of the (R)-6,7-dihydroxy-1,1-dimethyl isochroman-3-formyl-AA. Therefore, the invention discloses an application of the (R)-6,7-dihydroxy-1,1-dimethyl isochroman-3-formyl-AA in preparation of antithrombotic drugs.
Dihydroxy dimethyl isochroman-3-formyl polar amino acid as well as preparation, thrombolytic activity and application thereof
-
Paragraph 0018-0019, (2021/01/29)
The invention discloses eight (R)-6,7-dihydroxy-1,1-dimethyl isochroman-3-formyl-AA (AA is L-Asp, L-Glu, L-Lys, L-Asn, L-Gln, L-Arg, L-Ser and L-Thr residues) represented by the following formula, anda preparation method and a thrombolytic effect of the (R)-6,7-dihydroxy-1,1-dimethyl isochroman-3-formyl-AA, and thus the invention discloses an application of the (R)-6,7-dihydroxy-1,1-dimethyl isochroman-3-formyl-AA in preparation of thrombolytic drugs.
Dihydroxy dimethyl isochroman-3-formyl aromatic amino acid and preparation, thrombolytic activity and application thereof
-
Paragraph 0015; 0017-0018, (2020/12/14)
The invention discloses four (R)-6, 7-dihydroxy-1, 1-dimethyl isochroman-3-formyl-AA (AA is L-Phe, L-His, L-Trp and L-Tyr residues) of the following formula, a preparation method thereof and an application of the (R)-6, 7-dihydroxy-1, 1-dimethyl isochroman-3-formyl-AA in thrombolytic drug preparation. Therefore, the invention discloses an application of the compounds in preparation of thrombolyticdrugs.
